Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xenazine

Teva’s Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

- PMLiVE

Teva offloads women’s health unit in quickfire deals

The Israeli pharma group is also set to sell its oncology and pain business

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

FDA approves first substance use mobile medical application

Pear Therapeutics' Reset device offers cognitive behavioural therapy

- PMLiVE

GSK’s Shingrix sails through FDA advisory committee

Shingles vaccine data proved safe and effective, says the panel

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

FDA poised to start digital health pilot

Forms a key part of the agency's new digital innovation action plan

- PMLiVE

FDA clears Teva’s tardive dyskinesia drug Austedo

The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza

- PMLiVE

Lundbeck partners with 23andMe on first-of-its-kind study

Psychiatry collaboration will combine data from genetics, cognitive tests and online surveys

- PMLiVE

Ironwood claims FDA OK for former AZ gout drug

Duzallo will be launched in the US before the end of this year

- PMLiVE

Teva to cut 7000 jobs, close 15 manufacturing sites

Missed second-quarter sales expectations prompt the cutbacks

- PMLiVE

Setback for J&J as FDA panel turns down arthritis drug sirukumab

US regulator concerned with the drug’s safety

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links